more_vert
Delayed diagnosis of juvenile idiopathic arthritis remains a significant and preventable cause of harm for Australian children. With many waiting months, some years, for specialist assessment, earlier recognition in primary care is critical to reducing long-term disability and improving outcomes.
Juvenile idiopathic arthritis is among the most common chronic diseases of childhood in Australia, affecting an estimated 6 000 to 10 000 children under the age of 16, a prevalence comparable to type 1 diabetes. Despite this, timely diagnosis remains a persistent challenge across the healthcare system.
The burden of disease is substantial and multifaceted. Findings from the JAFA IMPACT Study 2023 indicate that 80% of affected children experience daily pain, more than half live with co-existing mental health conditions such as anxiety and depression, and 46% require assistance with activities of daily living. Educational participation is also significantly affected, with school-aged children missing approximately 12% of school days annually.
A key concern is the delay to diagnosis, with Australian children waiting an average of 10 months before receiving appropriate assessment, according to the IMPACT study. During this period, ongoing inflammation will cause pain and reduced physical functioning and may result in vision loss secondary to juvenile idiopathic arthritis-associated uveitis. Early symptoms, including joint swelling, stiffness, limping and fatigue, can be misattributed to injury or “growing pains,” contributing to missed opportunities for early intervention.
Research and clinical insights
Recent Australian research and clinical observations highlight that delayed diagnosis in juvenile idiopathic arthritis is driven by a combination of patient, clinician and system-level factors. These include low awareness of paediatric rheumatic disease, variability in symptom presentation, and limited access to specialist services.
Evidence from clinical cohorts and national collaborations involving organisations such as the Australian Paediatric Rheumatology Group (APRG) and Juvenile Arthritis Foundation Australia (JAFA) demonstrates that children commonly present to multiple healthcare providers before referral to paediatric rheumatology. During this time, disease progression often continues unchecked.
Delayed diagnosis can be associated with significant and sometimes irreversible complications. Persistent inflammation can lead to joint damage, contractures and growth disturbances. In addition, uveitis, a known extra-articular manifestation of juvenile idiopathic arthritis, may be asymptomatic but can result in permanent vision impairment if not detected early. These findings reinforce the importance of early identification and prompt referral.
To address these gaps, practical, clinician-focused interventions have been developed. The Early Diagnosis HCP Hub, an initiative led by JAFA in collaboration with the APRG, provides evidence-based guidance tailored to frontline healthcare professionals. The platform includes red flag indicators, structured assessment prompts, screening recommendations, including uveitis risk, and clear referral pathways to paediatric rheumatology services.
The effectiveness of such initiatives lies in their focus on real-world clinical decision making. General practitioners, emergency physicians, physiotherapists and other allied health professionals are typically the first point of contact for children with musculoskeletal complaints. Enhancing their ability to recognise persistent or atypical symptoms is critical to reducing diagnostic delay.
In addition, geographic disparities in access to paediatric rheumatology services may influence outcomes and limit national consistency in care.
Looking forward
Addressing delayed diagnosis in juvenile idiopathic arthritis requires coordinated action across policy, service delivery and clinical practice.
At a system level, increased investment in paediatric rheumatology services is essential, as highlighted in the 2022 interim report of the Parliamentary Inquiry into Childhood Rheumatic Diseases. Workforce shortages and uneven geographic distribution continue to limit timely access to specialist care, particularly in regional and rural areas. Expanding specialist capacity and improving referral pathways should be prioritised.
Equally important is strengthening diagnostic capability in primary care. Targeted education for general practitioners and allied health professionals, supported by tools such as the Early Diagnosis HCP Hub, should be embedded into continuing professional development. Earlier recognition of persistent musculoskeletal symptoms must become standard practice.
More broadly, a shift in clinical mindset is needed. Persistent and consistent joint symptoms in children — particularly when they interfere with physical functioning — should not be routinely attributed to benign causes without appropriate assessment. Duration, functional impact and symptom pattern should prompt consideration of inflammatory disease and, where appropriate, early referral.
Juvenile idiopathic arthritis represents a condition in which early diagnosis can significantly alter long-term outcomes. Reducing delays in recognition and referral offers a clear opportunity to prevent disability, improve quality of life, and reduce long-term health system burden. The priority now is translating existing knowledge into consistent, system-wide practice.
Associate Professor Jonathan Akikusa is a paediatric rheumatologist, clinical researcher and the head of the paediatric rheumatology service at the Royal Children’s Hospital.
Dr Akikusa is a founding member, and current Chair, of the Australian Paediatric Rheumatology Group (APRG) and the national lead primary investigator in several multi-centre international clinical drug trials of new immunomodulatory agents for paediatric rheumatic diseases.
The statements or opinions expressed in this article reflect the views of the authors and do not necessarily represent the official policy of the AMA, the MJA or InSight+ unless so stated.
Subscribe to the free InSight+ weekly newsletter here. It is available to all readers, not just registered medical practitioners.
If you would like to submit an article for consideration, send a Word version to mjainsight-editor@ampco.com.au.